Last updated on April 23, 2014 at 1:22 EDT

Cardiome Announces Commercialization Agreement With Tzamal Medical Group For Brinavess(TM) In Israel

September 17, 2013


VANCOUVER, Sept. 17, 2013 /PRNewswire/ – Cardiome Pharma Corp. (NASDAQ: CRME /
TSX: COM) today announced that its subsidiary, Cardiome Development AG,
has entered into an agreement with Tzamal Medical Ltd., to sell and
distribute BRINAVESS(TM) (vernakalant intravenous) exclusively in Israel.
Under the terms of the agreement, Tzamal Medical has agreed to specific
annual commercial goals for BRINAVESS. Financial details of the
agreement have not been disclosed.

“This agreement with Tzamal Medical reaffirms Cardiome’s commitment to
continue making BRINAVESS available worldwide, including markets
outside of Europe,” said Karim Lalji, Cardiome’s Chief Commercial
Officer. “We are pleased to have partnered with an industry leader and
look forward to leveraging Tzamal Medical’s expertise to commercialize
BRINAVESS in the Israeli market.”

“We are excited to be working with Cardiome to commercialize BRINAVESS
in Israel,” said Edi Steinberg, CEO at Tzamal BioPharma Ltd, the
pharmaceutical arm of Tzamal Medical Ltd. “BRINAVESS will be a great
addition to our current line of hospital intensive and emergency care
drug products. Emergency room physicians and surgeons need additional
treatment options for Atrial Fibrillation (AF).”

The initial term of this commercial agreement begins September 15, 2013
for the duration of three years and is renewable on an annual basis, or
longer, thereafter.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a biopharmaceutical company dedicated to the
discovery, development and commercialization of new therapies that will
improve the health of patients around the world. Cardiome has one
marketed product, BRINAVESS(TM) (vernakalant IV), approved in Europe and other territories for the
rapid conversion of recent onset atrial fibrillation to sinus rhythm in

Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto
Stock Exchange (COM). For more information, please visit our web site
at www.cardiome.com.

About Tzamal Medical Group

Tzamal Medical Group is a leading private group of companies providing
pharmaceuticals, medical devices and equipment for the healthcare
industry with over 70 sales representative serving that market. Tzamal
Medical Group generates sales of over $35 million annually with a
distinctive multidisciplinary presence in cardiology and partnerships
with leading manufacturers such as B. Braun, Vascular Solution, Inspire
MD, Angioscore, and Iroko/Correvio. Tzamal Medical Group is a leader in
promoting global healthcare and creating leverage both in the Israeli
and global medical markets. For more information, visit www.tzamal-medical.co.il.

    Forward-Looking Statement Disclaimer
    Certain statements in this news release contain forward-looking
    statements within the meaning of the Private Securities Litigation
    Reform Act of 1995 or forward-looking information under applicable
    Canadian securities legislation that may not be based on historical
    fact, including without limitation statements containing the words
    "believe", "may", "plan", "will", "estimate", "continue", "anticipate",
    "intend", "expect" and similar expressions.  Forward- looking
    statements may involve, but are not limited to, comments with respect
    to our objectives and priorities for the remainder of 2013 and beyond,
    our strategies or future actions, our targets, expectations for our
    financial condition and the results of, or outlook for, our operations,
    research and development and product and drug development. Such
    forward-looking statements involve known and unknown risks,
    uncertainties and other factors that may cause the actual results,
    events or developments to be materially different from any future
    results, events or developments expressed or implied by such
    forward-looking statements. Many such known risks, uncertainties and
    other factors are taken into account as part of our assumptions
    underlying these forward-looking statements and include, among others,
    the following: general economic and business conditions in the United
    States, Canada, Europe, and the other regions in which we operate;
    market demand; technological changes that could impact our existing
    products or our ability to develop and commercialize future products;
    competition; existing governmental legislation and regulations and
    changes in, or the failure to comply with, governmental legislation and
    regulations; availability of financial reimbursement coverage from
    governmental and third-party payers for products and related
    treatments; adverse results or unexpected delays in pre-clinical and
    clinical product development processes; adverse findings related to the
    safety and/or efficacy of our products or products; decisions, and the
    timing of decisions, made by health regulatory agencies regarding
    approval of our technology and products; the requirement for
    substantial funding to expand commercialization activities; and any
    other factors that may affect our performance. In addition, our
    business is subject to certain operating risks that may cause any
    results expressed or implied by the forward-looking statements in this
    presentation to differ materially from our actual results. These
    operating risks include: our ability to attract and retain qualified
    personnel; our ability to successfully complete pre-clinical and
    clinical development of our products; changes in our business strategy
    or development plans; intellectual property matters, including the
    unenforceability or loss of patent protection resulting from
    third-party challenges to our patents; market acceptance of our
    technology and products; our ability to successfully manufacture,
    market and sell our products; the availability of capital to finance
    our activities; and any other factors described in detail in our
    filings with the Securities and Exchange Commission available at
    www.sec.gov and the Canadian
    securities regulatory authorities at
    www.sedar.com. Given these risks,
    uncertainties and factors, you are cautioned not to place undue
    reliance on such forward-looking statements and information, which are
    qualified in their entirety by this cautionary statement. All
    forward-looking statements and information made herein are based on our
    current expectations and we undertake no obligation to revise or update
    such forward-looking statements and information to reflect subsequent
    events or circumstances, except as required by law.


SOURCE Cardiome Pharma Corp.

Source: PR Newswire